CNTN1 and breast cancer: For the ROC curve for the NRXN-1 w.r.t early stage versus advanced stage of breast cancer at the best possible cutoff value of a 4.5-fold increase in NRXN-1 expression, the sensitivity and specificity were 93% and 90%, respectively (AUC = 0.97, p < 0.0001) (Table 5) and for ROC curve for CNTN-1 w.r.t early stage versus advanced stage of breast cancer at best possible cutoff value of a 3.12-fold increase in CNTN 1 expression, the sensitivity and specificity were 90% and 82%, respectively (AUC = 0.95, p < 0.0001) (Figure 4).